“But you put all that together, it's -- together with the -- with the funding for HIV testing, that's over $1 billion of I guess, a headwind. And even with that $1 billion, we're still forecasting high single-digit growth and absorbing the impact of tariffs, which we now expect to be just $200 million of impact.”

In context

“rket share kind of recovery process here. So really, the challenge that we've had is twofold here. It's really drop-off on our COVID testing sales and some challenges in the China core lab market together with some changes that we've seen in the [ Eurosport ] funding for HIV testing. So you -- you look at that and say, okay, I'm not sure these are impacts that are 100% definite in the second half of the year, but I'm not going to sit here and try and kind of forecast what COVID testing is going to do. We had expected to see a China recovery in volume. We knew the price impact in China Core Lab, David, and we rolled that into our guidance. We had expected a market volume recovery to start happening in quite frankly, starting in Q2. We haven't seen that. So we've moved that out into [ Q4 ]. But you put all that together, it's -- together with the -- with the funding for HIV testing, that's over $1 billion of I guess, a headwind. And even with that $1 billion, we're still forecasting high single-digit growth and absorbing the impact of tariffs, which we now expect to be just $200 million of impact. FX, as Phil kind of said in his comments, is still a headwind versus prior year on the EPS side, but much less of a headwind than what we originally kind of anticipated back in January and quite frankly [ people], too. So that helps offset some of the tariff impact. So I put this all together, and you got -- it will be nice, David, to lap these to see these headwinds behind us next year. And then as you look to next year, you got all this great launch activity across all the businesses, whether it's Vault in the U.S., [ TACTIFLexDuo ] internationally, the dual analyte sensor, the launch of the new Alinity system the biosimilar kind of rollout. So I look at all of that and I say, okay, you've got this headwind that we're facing here. Still we're committed to high single-digit growth and do”